Q1 2017 Pfenex Inc Earnings Call

8/5/2017 16:30

Conference Call Pfenex Inc

Pfenex Inc Conference call or earnings call will be held on May 8, 2017 During the earnings conference call's session Pfenex Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Pfenex Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a clinical-stage biotechnology company engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Our lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis, marketed by Genentech, Inc., a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases, achieved approximately $4.5 billion in global product sales in 2014. For PF582, we are conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, with our collaboration partner, Hospira, Inc., or Hospira, a subsidiary of Pfizer Inc. (collectively with Hospira, "Pfizer"). Pfizer is responsible for manufacturing, clinical studies and commercialization of PF582 globally upon successful receipt of marketing approval. Our next most advanced product candidates are PF530 and PF708.    
Read more Conference Call

Pfenex Inc (PFNX)

10790 Roselle Street, San Diego California 92121, United States